共5页/93条首页上一页123下一页尾页
回复:93 阅读:11606
B20Breast basal-like carcinoma (cqz 6)

cqzhao 离线

帖子:5518
粉蓝豆:1071
经验:5755
注册时间:2008-09-29
加关注  |  发消息
楼主 发表于 2008-11-27 12:21|举报|关注(0)
浏览排序[ 顺序 逆序 楼主 支持 精彩 ]  快捷回复
姓    名: ××× 性别:   年龄:  
标本名称:  
简要病史:  
肉眼检查:  

Old women with a breast lesion.

Fig 1 20x

Fig 2-3: 100x

Fig 4-5: 200x

Fig 6. 400x

What are your differential diagnoses?

  • Breast basal-like carcinoma (cqz 6)图1
    图1
  • Breast basal-like carcinoma (cqz 6)图2
    图2
  • Breast basal-like carcinoma (cqz 6)图3
    图3
  • Breast basal-like carcinoma (cqz 6)图4
    图4
  • Breast basal-like carcinoma (cqz 6)图5
    图5
  • Breast basal-like carcinoma (cqz 6)图6
    图6
标签:
本帖最后由 于 2009-02-17 09:50:00 编辑
0
添加参考诊断
×参考诊断
  

heye 离线

帖子:63
粉蓝豆:39
经验:173
注册时间:2011-12-15
加关注  |  发消息
93 楼    发表于2013-03-15 16:59:04举报|引用
返回顶部 | 快捷回复
本帖最后由 heye 于 2013-03-17 09:04:14 编辑

http://www.west-info.eu/files/studio-di-nature-cancro-al-seno.pdf

http://www.nature.com/nature/journal/v490/n7418/full/nature11412.html

 

 

0
回复
signature
binglihe

Tim 离线

帖子:24
粉蓝豆:1
经验:30
注册时间:2010-01-17
加关注  |  发消息
2 楼    发表于2010-01-17 10:50:00举报|引用
返回顶部 | 快捷回复
 学习
0
回复

fireplay 离线

帖子:31
粉蓝豆:33
经验:52
注册时间:2009-12-15
加关注  |  发消息
3 楼    发表于2010-01-16 20:19:00举报|引用
返回顶部 | 快捷回复

 经验少

学习啦

0
回复

skybobo 离线

帖子:1312
粉蓝豆:154
经验:2232
注册时间:2009-06-22
加关注  |  发消息
4 楼    发表于2009-07-25 23:04:00举报|引用
返回顶部 | 快捷回复
 
浸润性导管癌(粉刺样型)

0
回复
signature
病理乃医学之魂

cqzhao 离线

帖子:5518
粉蓝豆:1071
经验:5755
注册时间:2008-09-29
加关注  |  发消息
5 楼    发表于2009-07-07 22:29:00举报|引用
返回顶部 | 快捷回复
 Am J Surg Pathol. 2009 Apr 22. [Epub ahead of print]

Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers.

*Department of Pathology, Beth Israel Deaconess Medical Center daggerDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School parallelDepartments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA double daggerKlinik für Gynäkologie und Gynäkologische Onkologie, Dr Horst Schmidt Klinik, Wiesbaden, Germany section signDivision of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.

BACKGROUND: Over 80% of breast cancers in women with germline BRCA1 mutations are estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative ("triple negative") and most of these have a basal-like phenotype by expression profiling and immunophenotypic analysis. However, whether or not expression of biomarkers characteristic of basal-like breast cancers helps to define a subset of women with triple-negative breast cancers who are likely to harbor BRCA1 mutations is an unresolved issue. METHODS: We randomly identified 165 women from the Dana-Farber/Harvard Cancer Center SPORE annotated specimen bank with primary invasive, triple-negative breast cancers. Tissue microarrays were constructed by obtaining triplicate 0.6 mm cores from available paraffin blocks from 130 cases: only unstained slides were available for immunostaining from 35 cases. Slides cut from the tissue microarrays and the unstained slides were immunostained for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (to confirm triple-negative status) and for several markers that have been reported to be useful in defining the basal-like phenotype, including basal cytokeratins CK5/6, CK14, and CK17 and epidermal growth factor receptor (EGFR). Full sequencing analysis for BRCA1 germline mutations was performed on blood specimens from all cases. The final study population consisted of 144 cases in which (1) triple-negative status was confirmed; (2) there was sufficient material for analysis of basal cytokeratins and EGFR; and (3) germline BRCA1 mutation status was known. RESULTS: Among these triple-negative breast cancer cases, 97 (67%) expressed one or more basal cytokeratins and 102 (71%) showed EGFR expression. Basal cytokeratin expression was detected in 65% of the tumor from the 20 BRCA1 mutation carriers and in 68% of the cancers from women without mutations (P=NS). EGFR expression was identified in a similar proportion of tumors from women with and without BRCA1 mutations (75% vs. 72%, P=NS). CONCLUSIONS: Basal cytokeratin and EGFR expression are both highly prevalent among triple-negative breast cancers. The frequency of expression of basal cytokeratins and EGFR was similar in women with and without BRCA1 mutations. Therefore, although the expression of basal cytokeratins and/or EGFR can be used to identify triple-negative breast cancers that have a basal-like phenotype, expression of these markers alone is not sufficient to distinguish which women with triple-negative breast cancers are likely to harbor BRCA1 germline mutations.

0
回复

cqzhao 离线

帖子:5518
粉蓝豆:1071
经验:5755
注册时间:2008-09-29
加关注  |  发消息
6 楼    发表于2009-03-03 01:40:00举报|引用
返回顶部 | 快捷回复
本帖最后由 于 2009-03-03 01:47:00 编辑

 You know all sugjects. I only know some breast/gyn/cyto and no others. So you are more valuable.

In fact pathologists need to sign out all even in most hospitals in the US. Only in few very large academic centers, pathologists sign out for their own subspecielties.

Thank for teaching me the word. No I know a new chinese word.

Agree that pathologists 要广泛地学习,仔细地询问,缜密地思考,明确地分辨,踏踏实实地实践.

You pick a name which is consistent with your personality.

0
回复

笃行者 离线

帖子:2689
粉蓝豆:59
经验:3020
注册时间:2006-10-04
加关注  |  发消息
7 楼    发表于2009-03-02 22:16:00举报|引用
返回顶部 | 快捷回复
以下是引用cqzhao在2009-3-2 20:39:00的发言:

  笃行者 ,

……

 笃: how to call this word?

Why did you choose the user name  笃行者 ? Could u let us know if u do not mind.

哈哈,(du三声,音同“赌”),忠实、专心、一心一意的意思:———笃行而不倦。

博学之,审问之,慎思之,明辨之,笃行之。——《中庸》

意思是说:要广泛地学习,仔细地询问,缜密地思考,明确地分辨,踏踏实实地实践。

我们病理医生不正是这样做的吗。这也是我的座右铭。而其中最主要的我认为还是“笃行”,所以我就是“笃行者”。

呵呵,见笑见笑。

0
回复
signature
博学之,审问之,慎思之,明辨之,笃行之。

笃行者 离线

帖子:2689
粉蓝豆:59
经验:3020
注册时间:2006-10-04
加关注  |  发消息
8 楼    发表于2009-03-02 21:57:00举报|引用
返回顶部 | 快捷回复
本帖最后由 于 2009-03-03 19:53:00 编辑
以下是引用cqzhao在2009-3-2 20:39:00的发言:

  笃行者 ,

Thank you. From your discussion in many topics, I can tell you are an experienced and excellent breast pathologist.

 ……

不敢当啊赵老师,您才是真正的专家,我只不过是被“赶上架的鸭子”而已。^_^(∩_∩)哈哈!我也不是专门研究乳腺病理的,只是对此比较感兴趣而已。国内多数医院还没有分得这么细,我们必须从头到脚、从里到外、从皮到骨、从基础到临床、从原始到现代……都得熟悉才行。
0
回复
signature
博学之,审问之,慎思之,明辨之,笃行之。

cqzhao 离线

帖子:5518
粉蓝豆:1071
经验:5755
注册时间:2008-09-29
加关注  |  发消息
9 楼    发表于2009-03-02 20:39:00举报|引用
返回顶部 | 快捷回复

  笃行者 ,

Thank you. From your discussion in many topics, I can tell you are an experienced and excellent breast pathologist.

 笃: how to call this word?

Why did you choose the user name  笃行者 ? Could u let us know if u do not mind.

0
回复

笃行者 离线

帖子:2689
粉蓝豆:59
经验:3020
注册时间:2006-10-04
加关注  |  发消息
10 楼    发表于2009-03-02 20:29:00举报|引用
返回顶部 | 快捷回复

 代表广大网友谢谢赵老师!不仅提供了许多非常好的病例,并且作了精彩的总结,图文并茂,受益匪浅!

认真复习该贴,就基本可以掌握基底细胞样乳腺癌的诊断要点。

0
回复
signature
博学之,审问之,慎思之,明辨之,笃行之。

笃行者 离线

帖子:2689
粉蓝豆:59
经验:3020
注册时间:2006-10-04
加关注  |  发消息
11 楼    发表于2009-03-02 20:23:00举报|引用
返回顶部 | 快捷回复
本帖最后由 于 2009-04-17 20:54:00 编辑  

 Dr. Zhao:

Thank you very much. I learn a lot from these typical cases.

0
回复
signature
博学之,审问之,慎思之,明辨之,笃行之。

cqzhao 离线

帖子:5518
粉蓝豆:1071
经验:5755
注册时间:2008-09-29
加关注  |  发消息
12 楼    发表于2009-02-08 22:18:00举报|引用
返回顶部 | 快捷回复
以下是引用kint123在2009-2-8 20:53:00的发言:

 搞科研的多是中国人,成果多在国外出,这是现状

说起来,我们缺乏突破性的研究成果

There are many Chinese doing research in the lab in the US. However we can not say that most people who do the research are Chinese abroad
0
回复

kint123 离线

帖子:1611
粉蓝豆:237
经验:2086
注册时间:2009-01-31
加关注  |  发消息
13 楼    发表于2009-02-08 20:53:00举报|引用
返回顶部 | 快捷回复

 搞科研的多是中国人,成果多在国外出,这是现状

说起来,我们缺乏突破性的研究成果

0
回复
signature
The More We See, The Less We Know!

cqzhao 离线

帖子:5518
粉蓝豆:1071
经验:5755
注册时间:2008-09-29
加关注  |  发消息
14 楼    发表于2009-02-07 23:42:00举报|引用
返回顶部 | 快捷回复
以下是引用kint123在2009-2-7 22:32:00的发言:

 也就是说仅用于癌或非癌的鉴别诊断问题?

今天看了一篇有关“gene-expression profiling”的review,感觉世界发展太快了,有的东西国内跟不上

We will. We can have Shenzhou #7. We will catch up in future if all Chinese  can realize the distance and work in the correct ways. I have a claasmate who is full professor and Chair of one department in one medical school in China. She is doing the research in a Lab in the US as a visiting schalor with money paid by China. She called me last week and mentioned the her feeling about the basic research conditions in these two countries.
0
回复

kint123 离线

帖子:1611
粉蓝豆:237
经验:2086
注册时间:2009-01-31
加关注  |  发消息
15 楼    发表于2009-02-07 22:32:00举报|引用
返回顶部 | 快捷回复

 也就是说仅用于癌或非癌的鉴别诊断问题?

今天看了一篇有关“gene-expression profiling”的review,感觉世界发展太快了,有的东西国内跟不上

0
回复
signature
The More We See, The Less We Know!

cqzhao 离线

帖子:5518
粉蓝豆:1071
经验:5755
注册时间:2008-09-29
加关注  |  发消息
16 楼    发表于2009-02-07 12:52:00举报|引用
返回顶部 | 快捷回复

 We use myoepithelial markers to rule out or confirm invasive carcinoma for some uncertained cases. Routinely we use two markers, p63 and smoth muscle myosin heavy chain.

We do not use myoepithelial markers for basal-like carcinoma.

0
回复

kint123 离线

帖子:1611
粉蓝豆:237
经验:2086
注册时间:2009-01-31
加关注  |  发消息
17 楼    发表于2009-02-07 12:00:00举报|引用
返回顶部 | 快捷回复

 Dr. ZHAO

我看你们的工作中并没有采用肌上皮标记,这是为什么呢?仅仅是因为阳性率低吗?

0
回复
signature
The More We See, The Less We Know!

杨宝军 离线

帖子:1631
粉蓝豆:31
经验:1891
注册时间:2007-02-10
加关注  |  发消息
18 楼    发表于2009-02-06 23:59:00举报|引用
返回顶部 | 快捷回复
 太精彩了
0
回复

cqzhao 离线

帖子:5518
粉蓝豆:1071
经验:5755
注册时间:2008-09-29
加关注  |  发消息
19 楼    发表于2009-02-06 22:59:00举报|引用
返回顶部 | 快捷回复
以下是引用huangzhx在2009-2-6 21:20:00的发言:

 结合免疫组化结果,考虑是否有肉瘤样分化的成分。

All basal-like carcinomas are positve for general epithelial markers and some basal-like markers. They are no related to sarcoma.
0
回复

huangzhx 离线

帖子:331
粉蓝豆:1857
经验:732
注册时间:2008-05-21
加关注  |  发消息
20 楼    发表于2009-02-06 21:20:00举报|引用
返回顶部 | 快捷回复
 结合免疫组化结果,考虑是否有肉瘤样分化的成分。
0
回复
回复:93 阅读:11606
共5页/93条首页上一页123下一页尾页
【免责声明】讨论内容仅作学术交流之用,不作为诊疗依据,由此而引起的法律问题作者及本站不承担任何责任。
快速回复
进入高级回复
您最多可输入10000个汉字,按 "Ctrl" + "Enter" 直接发送
搜索回复/乘电梯 ×
按内容
按会员
乘电梯
合作伙伴
友情链接